 Connection
Frederick Masoudi to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Frederick Masoudi has written about Randomized Controlled Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.822 |
|
|
|
-
Jones WS, Roe MT, Antman EM, Pletcher MJ, Harrington RA, Rothman RL, Oetgen WJ, Rao SV, Krucoff MW, Curtis LH, Hernandez AF, Masoudi FA. The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. J Am Coll Cardiol. 2016 10 25; 68(17):1898-1907.
Score: 0.311
-
Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, Ordin DL, Krumholz HM. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J. 2003 Aug; 146(2):250-7.
Score: 0.124
-
Masoudi FA, Calkins H, Kavinsky CJ, Drozda JP, Gainsley P, Slotwiner DJ, Turi ZG. 2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview. J Am Coll Cardiol. 2015 Sep 29; 66(13):1497-513.
Score: 0.071
-
Maddox TM, Masoudi FA, Oetgen WJ, Rumsfeld JS. The Capacity of Evidence to Inform Practice: The Rapid Registry Response (RRR) Initiative. J Am Coll Cardiol. 2015 May 26; 65(20):2252-3.
Score: 0.070
-
Bapoje SR, Bahia A, Hokanson JE, Peterson PN, Heidenreich PA, Lindenfeld J, Allen LA, Masoudi FA. Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail. 2013 Mar; 6(2):166-73.
Score: 0.060
-
Freeman JV, Masoudi FA. Effectiveness of implantable cardioverter defibrillators and cardiac resynchronization therapy in heart failure. Heart Fail Clin. 2013 Jan; 9(1):59-77.
Score: 0.059
-
Peterson PN, Masoudi FA. Cardiovascular disease and the elderly: can the evidence base avoid irrelevance? Eur Heart J. 2007 Jun; 28(11):1277-8.
Score: 0.040
-
Masoudi FA, Gross CP, Wang Y, Rathore SS, Havranek EP, Foody JM, Krumholz HM. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation. 2005 Jul 05; 112(1):39-47.
Score: 0.035
-
McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, Heckman GA, Howlett JG, Koshman SL, Lepage S, Mielniczuk L, Moe GW, O'Meara E, Swiggum E, Toma M, Zieroth S, Anderson K, Bray SA, Clarke B, Cohen-Solal A, D'Astous M, Davis M, De S, Grant ADM, Grzeslo A, Heshka J, Keen S, Kouz S, Lee D, Masoudi FA, McKelvie R, Parent MC, Poon S, Rajda M, Sharma A, Siatecki K, Storm K, Sussex B, Van Spall H, Yip AMC. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol. 2021 04; 37(4):531-546.
Score: 0.026
-
O'Meara E, McDonald M, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, Grzeslo A, Heckman GA, Howlett JG, Koshman SL, Lepage S, Mielniczuk LM, Moe GW, Swiggum E, Toma M, Virani SA, Zieroth S, De S, Matteau S, Parent MC, Asgar AW, Cohen G, Fine N, Davis M, Verma S, Cherney D, Abrams H, Al-Hesayen A, Cohen-Solal A, D'Astous M, Delgado DH, Desplantie O, Estrella-Holder E, Green L, Haddad H, Harkness K, Hernandez AF, Kouz S, LeBlanc MH, Lee D, Masoudi FA, McKelvie RS, Rajda M, Ross HJ, Sussex B. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. Can J Cardiol. 2020 02; 36(2):159-169.
Score: 0.024
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|